Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in China, has announced that it has received a Category III medical device license from the National Medical Products Administration (NMPA) for its newly developed vena cava filter. This device is designed to be percutaneously inserted through the femoral or jugular vein, aiming to prevent pulmonary embolism (PE) caused by thrombus detachment in the inferior vena cava system.
The vena cava filter is indicated for several patient groups, including:
- Those who have already developed PE or thrombosis in the specified veins and have conditions such as: (1) contraindications to anticoagulant therapy, (2) complications like bleeding during anticoagulant therapy, and (3) recurrent PE despite sufficient anticoagulation treatment or inability to achieve sufficient anticoagulation due to various reasons.
- Patients presenting with PE and lower limb deep vein thrombosis.
- Cases where there are free-floating clots or a significant number of clots in the iliac, femoral, or inferior vena cava.
- Patients diagnosed with thrombophilia who are experiencing recurrent PE.
- Those with acute deep vein thrombosis of the lower limbs requiring transcatheter thrombolysis and thrombus clearance.- Flcube.com
